Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid substitution therapy in rifampicin-resistant pulmonary tuberculosis when linezolid is unsuitable
ChiCTR2400090645Phase 4Recruiting
- Sponsor
- Guangzhou Chest Hospital
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of contezolid in Rifampicin-resistant pulmonary tuberculosis (RR-PTB), sponsored by Guangzhou Chest Hospital. Primary endpoint: Sputum culture conversion to negative. Started Oct 2024; status: recruiting.
02
Drugs
contezolid
03
Conditions
Rifampicin-resistant pulmonary tuberculosis (RR-PTB)
Beyond the preview
Go deeper on ChiCTR2400090645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090645.